咽头炎治疗市场 - 全球产业规模、份额、趋势、机会及预测（按疾病类型、药物类别、分销管道、地区和竞争格局划分，2021-2031年）

全球咽头炎治疗市场预计将从 2025 年的 24.9 亿美元成长到 2031 年的 32.7 亿美元，复合年增长率为 4.65%。

这个市场主要由抗生素、皮质类固醇和镇痛药等药物组成，这些药物用于缓解咽头炎发炎并控制发烧和喉咙痛等症状。推动市场扩张的关键因素包括全球细菌和病毒性呼吸道感染疾病的日益流行，以及患者对早期诊断重要性的认识不断提高，从而预防风湿热等严重併发症。这些潜在因素确保了治疗方法的稳定需求，使其区别于处方习惯和剂型偏好的暂时性变化。

然而，市场发展面临的主要障碍是日益严重的抗菌素抗药性问题，这需要实施更严格的抗菌素管理方案并减少滥用抗生素。这一沉重的疾病负担凸显了製定有效控制策略的迫切性。英国健康与安全执行局的数据也印证了这一持续存在的挑战，数据显示，仅在2024年1月至3月期间，英格兰就报告了12176例猩红热病例，这表明链球菌感染疾病的持续高发率需要得到妥善的医疗护理。

市场驱动因素

全球呼吸道感染和链球菌感染疾病的上升趋势是市场成长的主要驱动力，持续推高了对病原体感染疾病抗生素和缓解疼痛症状药物的需求。在后疫情时代，免疫力下降导致病原体快速传播，细菌性咽喉感染疾病捲土重来，这种需求激增的趋势特别显着。例如，《日本时报》2024年6月一篇题为「日本严重链球菌感染疾病创历史新高，达977例」的报导援引了日本国立感染疾病研究所的一份报告，指出截至6月初，日本已确诊977例严重链球菌感染疾病病例，超过了前一年的记录。如此高的感染率直接影响咽头炎咽头炎预防严重的后遗症。

同时，快速照护现场技术的进步和零售医疗服务的扩张正在从根本上改变医疗保健格局，使即时检测和治疗模式成为可能。这种转变改善了医疗服务的可近性，使药剂师能够快速区分病毒和细菌病因，从而合理地开立抗生素处方，减少不必要的就诊。根据英国国家医疗服务体系（NHS）英格兰分部2024年1月发布的「药局优先」（Pharmacy First）新闻稿，已有10265家社区药局註册推出治疗七种常见疾病的服务，其中包括咽喉痛的治疗。然而，满足这种分散的需求需要一条具有韧性的供应链，而目前由于生产限制，这条供应链正面临压力。据美国卫生系统药剂师协会（ASHP）称，2024年第一季药品短缺数量达到创纪录的323种，凸显了包括该领域使用的抗生素在内的基本药物库存面临的严峻挑战。

市场挑战

抗菌素抗药性日益严重的对全球咽头炎治疗市场构成重大挑战，迫使人们减少抗生素处方。不断上升的抗药性促使监管机构和医疗机构实施更严格的药物管理计划，以维持现有药物的疗效。这些措施积极限制在未确诊细菌感染的情况下对咽头炎使用经验性抗生素，并显着降低这种通常由病毒引起的疾病的用药频率。从随意用药转向标靶治疗，直接限制了市场的获利潜力。

持续的高抗药性水准进一步凸显了这些限制性通讯协定的必要性，确保合规要求将继续抑制市场成长。近期监测数据表明，滥用处方笺已不再可行，凸显了这项威胁的严重性。美国疾病管制与预防中心 (CDC) 于 2024 年发布的数据显示，由抗药性菌引起的感染疾病较疫情前基准值增加了总合%。这种抗药性不断增强的统计证据表明，有必要继续采取严格的抗菌药物管理干预措施，从而限制该领域药物治疗的广泛应用。

市场趋势

将人工智慧 (AI) 应用于非侵入性咽喉成像技术，透过智慧型手机远端检测链球菌感染疾病，正在革新早期诊断方式。这项技术无需患者亲自前往医院，即可拍摄咽喉影像，并利用机器学习演算法准确区分病毒和细菌病原体，从而消除了现场检测的瓶颈。此类创新为咽头炎患者提供了即时分流工具，显着减少了不必要的就医和抗生素滥用。根据 Mugglehead 网站 2025 年 1 月发表的题为「Light AI 开发用于诊断严重咽喉感染疾病的智慧型手机技术」的报导报道，Light AI 自 2024 年初以来已筹集 2500 万加元，用于开发一种能够以 97% 的准确率检测 A 组链球菌的演算法。

同时，消费者对天然草本配方的偏好日益增长，推动止痛方式从传统合成止痛药转向植物来源缓解症状。患者越来越倾向于选择含有高山植物、蜂蜜和薄荷醇等成分的含片和滴剂，作为更安全、副作用更少的急性咽头炎治疗方案。这种需求在新兴市场尤其显着，这些市场传统医学与现代零售通路融合，为成熟的草本品牌提供了强劲的销售动力。根据利口乐公司2025年5月发布的题为「利口乐2024年业绩稳健增长」的新闻稿，该公司在包括韩国、台湾和泰国在内的多个亚洲市场实现了两位数的增长，证实了市场对植物来源咽头炎治疗产品的需求不断增长。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球咽头炎治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依疾病类型（急性咽头炎、慢性咽头炎）
  • 依药物类别（抗生素、抗病毒药、皮质类固醇、抗真菌药物药物、其他）
  • 按分销管道（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美咽头炎治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲咽头炎治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区咽头炎治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲咽头炎治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲咽头炎治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球咽头炎治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Pfizer Inc
• Novartis AG
• Amneal Pharmaceuticals LLC
• Kenvue Inc.
• Thornton & Ross Ltd
• Reckitt Benckiser Group Plc
• Honibe
• Prestige Consumer Healthcare Inc.
• Traditional Medicinals, Inc.
• Lozen Pharma Pvt. Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Pharyngitis Treatment Market is expected to rise from USD 2.49 Billion in 2025 to USD 3.27 Billion by 2031 at a CAGR of 4.65%. This market centers on pharmaceutical interventions-such as antibiotics, corticosteroids, and analgesics-aimed at alleviating pharyngeal inflammation and managing symptoms like fever and sore throat. The primary forces driving this expansion include the increasing global prevalence of bacterial and viral respiratory infections, coupled with growing patient awareness regarding the importance of early diagnosis to prevent severe complications like rheumatic fever. These foundational factors guarantee a steady demand for therapeutic regimens, distinguishing them from transient changes in prescription habits or formulation preferences.

Conversely, a major obstacle hindering market development is the intensifying issue of antimicrobial resistance, which has required the implementation of stricter stewardship programs and a reduction in the indiscriminate use of antibiotics. This substantial disease burden highlights the urgent need for effective management strategies. Data from the UK Health Security Agency illustrates this persistent challenge, noting that 12,176 cases of scarlet fever were reported in England between January and March of 2024 alone, emphasizing the continuing volume of streptococcal infections that demand precise medical attention.

Market Driver

The increasing global frequency of respiratory and streptococcal infections serves as a primary catalyst for market growth, generating consistent demand for both pathogen-specific antibiotics and analgesic symptom relief. This surge is especially notable in post-pandemic environments where immunity gaps have facilitated rapid pathogen transmission and a resurgence of bacterial throat infections. For instance, a June 2024 article in The Japan Times titled 'Japan sees record 977 cases of severe strep infections' cited the National Institute of Infectious Diseases, which reported that the country documented 977 severe streptococcal infection cases by early June, exceeding the previous year's record. Such high infection rates compel healthcare systems to maintain robust inventories of therapeutic agents to treat acute pharyngeal inflammation and prevent severe sequelae, directly influencing procurement volumes for pharyngitis treatments.

At the same time, the treatment landscape is being fundamentally altered by advancements in rapid point-of-care diagnostics and the expansion of retail health services, which enable immediate test-and-treat models. This shift improves accessibility, allowing pharmacists to quickly distinguish between viral and bacterial etiology, thereby guiding appropriate antibiotic prescription and reducing unnecessary medical visits. As reported in an NHS England 'Pharmacy First' press release from January 2024, 10,265 community pharmacies registered to launch a service treating seven common conditions, specifically including sore throat management. However, meeting this decentralized demand requires a resilient supply chain, which is currently under pressure due to manufacturing constraints. The American Society of Health-System Pharmacists noted that in the first quarter of 2024, active drug shortages reached an all-time high of 323, highlighting critical inventory challenges for essential medications including antimicrobials used in this sector.

Market Challenge

The escalating problem of antimicrobial resistance acts as a significant barrier to the Global Pharyngitis Treatment Market by necessitating a reduction in the volume of antibiotic prescriptions. As resistance rates increase, regulatory agencies and healthcare institutions are enforcing stricter stewardship programs to maintain the efficacy of existing drugs. These measures actively discourage the empirical use of antibiotics for pharyngeal inflammation without confirmed bacterial etiology, significantly limiting the frequency of drug administration for a condition that is often viral. This transition from liberal prescription habits to targeted therapy directly constrains the market's revenue potential.

The persistence of high resistance levels reinforces the need for these restrictive protocols, ensuring that market growth remains dampened by compliance requirements. The severity of this threat is evident in recent surveillance data which underscores why indiscriminate prescribing is no longer viable. According to published data from the Centers for Disease Control and Prevention in 2024, infections caused by antimicrobial-resistant bacteria increased by a combined 20% compared to pre-pandemic baselines. This statistical evidence of rising resistance justifies the continued rigor of stewardship interventions, thereby capping the widespread utilization of pharmaceutical treatments in this sector.

Market Trends

The integration of Artificial Intelligence for non-invasive throat imaging is revolutionizing early diagnosis by facilitating remote, smartphone-based screening for streptococcal infections. This technology resolves the bottleneck of in-person testing by allowing patients to capture throat images which are analyzed by machine learning algorithms to distinguish between viral and bacterial etiology with high precision. Such innovations significantly reduce unnecessary clinic visits and antibiotic overuse by providing immediate, accessible triage tools for pharyngitis management. According to a January 2025 article in Mugglehead titled 'Light AI develops smartphone tech for diagnosing severe throat infection', Light AI has raised C$25 million since early 2024 to support the development of its algorithm which detects Streptococcus A with nearly 97% accuracy.

Concurrently, there is a growing consumer preference for natural and herbal formulations, driving a shift away from conventional synthetic analgesics toward plant-based symptom relief. Patients are increasingly seeking therapeutic lozenges and drops containing ingredients like alpine herbs, honey, and menthol, perceived as safer alternatives with fewer side effects for managing acute throat inflammation. This demand is particularly robust in emerging markets where traditional medicine aligns with modern retail availability, fostering strong sales for established herbal brands. According to a May 2025 press release from Ricola titled 'Ricola delivers solid results in 2024', the company achieved double-digit growth in many Asian markets such as South Korea, Taiwan, and Thailand, underscoring the expanding market demand for botanical pharyngitis treatments.

Key Market Players

• Pfizer Inc
• Novartis AG
• Amneal Pharmaceuticals LLC
• Kenvue Inc.
• Thornton & Ross Ltd
• Reckitt Benckiser Group Plc
• Honibe
• Prestige Consumer Healthcare Inc.
• Traditional Medicinals, Inc.
• Lozen Pharma Pvt. Ltd

Report Scope

In this report, the Global Pharyngitis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharyngitis Treatment Market, By Disease Type

• Acute Pharyngitis
• Chronic Pharyngitis

Pharyngitis Treatment Market, By Drug Class

• Antibiotics
• Antiviral Drugs
• Corticosteroids
• Antifungals
• Others

Pharyngitis Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Pharyngitis Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharyngitis Treatment Market.

Available Customizations:

Global Pharyngitis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharyngitis Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Acute Pharyngitis, Chronic Pharyngitis)
  • 5.2.2. By Drug Class (Antibiotics, Antiviral Drugs, Corticosteroids, Antifungals, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Pharyngitis Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pharyngitis Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Pharyngitis Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Pharyngitis Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Distribution Channel

7. Europe Pharyngitis Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pharyngitis Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Pharyngitis Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Pharyngitis Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Pharyngitis Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Pharyngitis Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Pharyngitis Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pharyngitis Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Pharyngitis Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Pharyngitis Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Pharyngitis Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Pharyngitis Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Pharyngitis Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pharyngitis Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Pharyngitis Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Pharyngitis Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Distribution Channel

10. South America Pharyngitis Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Drug Class
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pharyngitis Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Pharyngitis Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Pharyngitis Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pharyngitis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Amneal Pharmaceuticals LLC
• 15.4. Kenvue Inc.
• 15.5. Thornton & Ross Ltd
• 15.6. Reckitt Benckiser Group Plc
• 15.7. Honibe
• 15.8. Prestige Consumer Healthcare Inc.
• 15.9. Traditional Medicinals, Inc.
• 15.10. Lozen Pharma Pvt. Ltd

16. Strategic Recommendations

17. About Us & Disclaimer